


=> d 121  
 L21 HAS NO ANSWERS  
 L21 STR



REP G1=(0-5) CH2  
 REP G2=(1-7) CH2  
 VAR G3=3/2  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RSPEC 1  
 NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

=> d 111  
 L11 HAS NO ANSWERS  
 L11 SCR 1840

=> d hit 125


L25 ANSWER 1 OF 47 REGISTRY COPYRIGHT 2002 ACS

=> d his 125

(FILE 'REGISTRY' ENTERED AT 12:11:41 ON 25 JUL 2002)  
 L25 47 S L21 AND L11 FUL

L5 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2002 ACS  
 RN 200006-35-5 REGISTRY  
 CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C22 H25 N O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1967 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2002 ACS  
 RN 200006-27-5 REGISTRY  
 CN L-Proline, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C21 H25 N O3  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2002 ACS  
 RN 2133-40-6 REGISTRY  
 CN L-Proline, methyl ester, hydrochloride (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Proline, methyl ester, hydrochloride, L- (6CI, 7CI, 8CI)  
 OTHER NAMES:  
 CN (S)-Proline methyl ester hydrochloride  
 CN Methyl L-prolinate hydrochloride  
 CN Methyl prolinate hydrochloride  
 CN Methyl proline hydrochloride

FS STEREOSEARCH  
 DR 190017-88-0  
 MF C6 H11 N O2 . Cl H  
 CI COM  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,  
 CSCHEM, GMELIN\*, IFICDB, IFIPAT, IFIUDB, SYNTHLINE, TOXCENTER, USPAT2,  
 USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 CRN (2577-48-2)

Absolute stereochemistry. Rotation (-).






● HCl

588 REFERENCES IN FILE CA (1967 TO DATE)  
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 589 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

AN 1985:442656 CAPLUS  
 DN 103:42656  
 TI N-Substituted pyrrolidineacetic acids and their esters  
 IN Bondinell, William E.; Lafferty, John J.; Zirkle, Charles L.  
 PA Smithkline Beckman Corp., USA  
 SO U.S., 7 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4514414	A	19850430	US 1982-436232	19821025
OS	CASREACT 103:42656				
GI					



AB Pharmaceutical compns. useful as inhibitors of GABA [56-12-2] uptake comprise the title compds. I [R = cyclohexyl, thienyl, or (un)substituted Ph; R1 and R2 = H, Cl, F, Me, or MeO; R3 = H or Me; R4 = H or C1-3 alkyl; n = 2 or 3], II (R1, R2, R3, and R4 as above), and III (R1 and R4 as above) and their optical isomers. I were prepd. by the reaction of an alkenyl halide with an ester of an N-substituted pyrrolidineacetic acid (IV), II were prepd. by the reaction of IV with a diphenylalkyl group, and III were prepd. by the reaction of IV with an ester of an appropriately substituted phenylalkyne. Thus, a capsule formulation contained 1-(4,4-diphenyl-3-butenyl)-3-pyrrolidineacetic acid (I; R = Ph, R1-R4 = H) [89203-55-4] 50, Mg stearate 2, and lactose 200 mg/capsule.


IT **97182-43-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and hydrolysis of)

RN 97182-43-9 CAPLUS

CN 3-Pyrrolidineacetic acid, 1-[4-(3-chlorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



118

STN

09/763617

Page 1

12/02/2001

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal626gms

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 3 Feb 06 Engineering Information Encompass files have new names  
NEWS 4 Feb 16 TOXLINE no longer being updated  
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure  
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA  
NEWS 7 May 07 DGENE Reload  
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL  
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's  
DWPI and DPCI  
NEWS 10 Aug 23 In-process records and more frequent updates now in  
MEDLINE  
NEWS 11 Aug 23 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA  
NEWS 12 Aug 23 Adis Newsletters (ADISNEWS) now available on STN  
NEWS 13 Sep 17 IMSworld Pharmaceutical Company Directory name change  
to PHARMASEARCH  
NEWS 14 Oct 09 Korean abstracts now included in Derwent World Patents  
Index  
NEWS 15 Oct 09 Number of Derwent World Patents Index updates increased  
NEWS 16 Oct 15 Calculated properties now in the REGISTRY/ZREGISTRY File  
NEWS 17 Oct 22 Over 1 million reactions added to CASREACT  
NEWS 18 Oct 22 DGENE GETSIM has been improved  
NEWS 19 Oct 29 AAASD no longer available  
NEWS 20 Nov 19 New Search Capabilities USPATFULL and USPAT2  
NEWS 21 Nov 19 TOXCENTER(SM) - new toxicology file now available on STN  
NEWS 22 Nov 29 COPPERLIT now available on STN  
NEWS 23 Nov 29 DWPI revisions to NTIS and US Provisional Numbers  
NEWS 24 Nov 30 Files VETU and VETB to have open access  
  
NEWS EXPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,  
CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),  
AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Golam Shameem

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:08:50 ON 02 DEC 2001

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 13:09:06 ON 02 DEC 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 30 NOV 2001 HIGHEST RN 372937-30-9

DICTIONARY FILE UPDATES: 30 NOV 2001 HIGHEST RN 372937-30-9

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09763617.str

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



*example (18.1)*  
Page 30

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:09:38 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS  
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 5 TO 234  
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 13:09:47 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 38 TO ITERATE

100.0% PROCESSED 38 ITERATIONS  
SEARCH TIME: 00.00.01

3 ANSWERS

L3 3 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY  
133.56

TOTAL  
SESSION  
133.71

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:09:56 ON 02 DEC 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)



Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 2 Dec 2001 VOL 135 ISS 24  
FILE LAST UPDATED: 30 Nov 2001 (20011130/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> d his

(FILE 'HOME' ENTERED AT 13:08:50 ON 02 DEC 2001)

FILE 'REGISTRY' ENTERED AT 13:09:06 ON 02 DEC 2001

L1 STRUCTURE UPLOADED  
L2 1 S L1  
L3 3 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:09:56 ON 02 DEC 2001

=> s l3

L4 3 L3

=> d l4 ibib abs hit str

'STR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data

Golam Shameem

IPC ----- International Patent Classifications  
 MAX ----- ALL, plus Patent FAM, RE  
 PATS ----- PI, SO  
 SAM ----- CC, SX, TI, ST, IT  
 SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
 SCAN must be entered on the same line as the DISPLAY,  
 e.g., D SCAN or DISPLAY SCAN)  
 STD ----- BIB, IPC, and NCL  
  
 IABS ----- ABS, indented with text labels  
 IALL ----- ALL, indented with text labels  
 IBIB ----- BIB, indented with text labels  
 IMAX ----- MAX, indented with text labels  
 ISTD ----- STD, indented with text labels  
  
 OBIB ----- AN, plus Bibliographic Data (original)  
 OIBIB ----- OBIB, indented with text labels  
  
 SBIB ----- BIB, no citations  
 SIBIB ----- IBIB, no citations  
  
 HIT ----- Fields containing hit terms  
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
 containing hit terms  
 HITRN ----- HIT RN and its text modification  
 HITSTR ----- HIT RN, its text modification, its CA index name, and  
 its structure diagram  
 HITSEQ ----- HIT RN, its text modification, its CA index name, its  
 structure diagram, plus NTE and SEQ fields  
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
 its structure diagram  
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
 structure diagram, plus NTE and SEQ fields  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
 ENTER DISPLAY FORMAT (BIB):end

=> d 14 ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2001:132748 CAPLUS  
 DOCUMENT NUMBER: 134:178816  
 TITLE: Preparation of amino acid derivatives as  
 pharmaceuticals for treatment of neurological and  
 neuropsychiatric disorders  
 INVENTOR(S): Ognyanov, Vassil Iliya; Borden, Laurence A.; Bell,  
 Stanley Charles; Zhang, Jing  
 PATENT ASSIGNEE(S): Allelix Neuroscience Inc., USA  
 SOURCE: U.S., 52 pp., Cont.-in-part of U. S. Ser. No.656,063,

abandoned.  
CODEN: USXXAM

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6191165	B1	20010220	US 1997-866007	19970530
US 2001012857	A1	20010809	US 2001-757011	20010109
PRIORITY APPLN. INFO.:			US 1996-41503	P 19960531
			US 1996-41504	P 19960531
			US 1996-655912	B2 19960531
			US 1996-656063	B2 19960531
			US 1997-44387	P 19970227
			US 1997-70900	P 19970227
			US 1997-808754	B2 19970227
			US 1997-808755	A2 19970227
			US 1997-807682	A2 19970228
			US 1997-866007	A3 19970530

OTHER SOURCE(S): MARPAT 134:178816

AB Amino acid derivs. R2RxRyXR1NR3(R3\*)nCR4R4\*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminoxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3\* = alkyl, O; n = 0, 1; R4, R4\* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.


IT 200006-35-5P 200006-37-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)

RN 200006-35-5 CAPLUS

CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200006-37-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(4,4-diphenyl-3-butenyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Golam Shameem



REFERENCE COUNT:

29

REFERENCE(S):

- (1) Ali, F; J Med Chem 1985, V28, P653 CAPLUS
  - (2) Anon; DE 3010599 1980 CAPLUS
  - (3) Anon; BE 885303 1981 CAPLUS
  - (5) Anon; EP 0068544 A2 1983 CAPLUS
  - (6) Anon; EP 0221572 A2 1987 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:157915 CAPLUS

DOCUMENT NUMBER: 132:194656

TITLE:

Preparation of proline derivatives and related compounds as GABA uptake inhibitors

INVENTOR(S):

Wanner, Klaus; Fuelep, Guenther; Hoefner, Georg

PATENT ASSIGNEE(S):

Germany

SOURCE:

Ger. Offen., 36 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19840611	A1	20000309	DE 1998-19840611	19980905
WO 2000014064	A2	20000316	WO 1999-EP6486	19990903
WO 2000014064	A3	20000720		
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9959726	A1	20000327	AU 1999-59726	19990903
EP 1109783	A2	20010627	EP 1999-968664	19990903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.:


DE 1998-19840611 A 19980905

WO 1999-EP6486 W 19990903

OTHER SOURCE(S):

MARPAT 132:194656

GI



AB Title compds. [I; R1-R7 = H, OH, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) aryl, heteroaryl, etc.; R1R2 and/or R3R4 and/or R5R6 = (substituted) alkylidene, O; pairs of adjoining R1-R7 = double bond; X = CO2M, group physiol. convertible to CO2M; M = H, pharmaceutically acceptable cation; Z = Y3CO, Y2C:CR15, Y2C:NO; R15 = H, alkyl, halo; Y = (substituted) aryl, heteroaryl; A1 = (CR8R9)n, (substituted) alkylene, or a combination thereof; n .gtoreq.2; R8, R9 = H, alkyl, halo, OH, etc.; A2 = (CR10R11)m; R10, R11 = H, alkyl, halo; m .gtoreq.2], were prepd. as GABA uptake inhibitors (no data). Thus, L-proline Me ester hydrochloride (prepn. given), KI, K2CO3, and 4,4-diphenylbut-3-en-1-yl bromide were stirred 46 h in acetone to give 52.4% Me (S)-N-(4,4-diphenylbut-3-en-1-yl)pyrrolidine-2-carboxylate.


IT 200006-35-5P 259868-39-8P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of proline derivs. and related compds. as GABA uptake inhibitors)

RN 200006-35-5 CAPLUS

CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259868-39-8 CAPLUS

CN D-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT:

8

REFERENCE(S):

- (2) Anon; EP 0231996 A2 CAPLUS
- (3) Anon; EP 0236342 B1 CAPLUS
- (4) Anon; EP 0374801 A2 CAPLUS
- (5) Anon; US 4514414 CAPLUS
- (6) Anon; US 4610995 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:803807 CAPLUS

DOCUMENT NUMBER: 128:48490

Golam Shameem

TITLE: Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders

INVENTOR(S): ~~Ognjanov, Vassil Iliya~~; Borden, Laurence; Bell, Stanley Charles; Zhang, Jing

PATENT ASSIGNEE(S): Trophix Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 107 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9745115	A1	19971204	WO 1997-US9450	19970529
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2254833	AA	19971204	CA 1997-2254833	19970529
AU 9731530	A1	19980105	AU 1997-31530	19970529
AU 730789	B2	20010315		
EP 1014966	A1	20000705	EP 1997-926871	19970529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9709501	A	20001107	BR 1997-9501	19970529
NO 9805711	A	19981207	NO 1998-5711	19981207
PRIORITY APPLN. INFO.:				
			US 1996-655912	A 19960531
			US 1996-656063	A 19960531
			US 1997-808754	A 19970227
			US 1997-808755	A 19970227
			US 1997-807682	A 19970227
			WO 1997-US9450	W 19970529

OTHER SOURCE(S): MARPAT 128:48490

AB Amino acid derivs. R2RxRyXR1NR3(R3\*)nCR4R4\*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminoxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3\* = alkyl, O; n = 0, 1; R4, R4\* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.

IT 200006-35-5P 200006-37-7P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)

RN 200006-35-5 CAPLUS

CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200006-37-7 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(4,4-diphenyl-3-butenyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
13.55	147.26

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.76	-1.76

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:11:33 ON 02 DEC 2001

Connection closed by remote host

=> s 125

L26 11 L25

=> s 126 and 120

L27 1 L26 AND L20

=> d bib

L27 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

AN 2000:157915 CAPLUS

DN 132:194656

TI Preparation of proline derivatives and related compounds as GABA uptake inhibitors

IN Wanner, Klaus; Fuelep, Guenther; Hoefner, Georg

PA Germany

SO Ger. Offen., 36 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19840611	A1	20000309	DE 1998-19840611	19980905
	WO 2000014064	A2	20000316	WO 1999-EP6486	19990903
	WO 2000014064	A3	20000720		
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9959726	A1	20000327	AU 1999-59726	19990903
	EP 1109783	A2	20010627	EP 1999-968664	19990903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	DE 1998-19840611	A	19980905		
	WO 1999-EP6486	W	19990903		

OS MARPAT 132:194656

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 126 not 127

L28 10 L26 NOT L27

=> d bib abs hitstr 10

L28 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 1984:114852 CAPLUS

DN 100:114852

TI Novel inhibitors of .gamma.-aminobutyric acid (GABA) uptake:  
Anticonvulsant actions in rats and mice

AU Yunger, Libby M.; Fowler, Philip J.; Zarevics, Peter; Setler, Paulette E.  
CS Dep. Pharmacol., Smith Kline and French Lab., Philadelphia, PA, USA

SO J. Pharmacol. Exp. Ther. (1984), 228(1), 109-15

CODEN: JPETAB; ISSN: 0022-3565

DT Journal

LA English

AB SKF 89976A [N-(4,4-diphenyl-3-butenyl)-nipecotic acid] [85375-85-5] and SKF 100330A [N-(4,4-diphenyl-3-butenyl)-guvacine] [85375-88-8] represent a series of potent, orally active inhibitors of GABA [56-12-2] uptake. These compds. were also potent anticonvulsants when administered either orally or i.p. to rats. Both compds. attenuated the forelimb extensor component of bicuculline-induced convulsions, but had no effect on strychnine-induced convulsions, indicating that they were acting through a



GABAergic mechanism in vivo. Two animals models known to indicate anticonvulsant efficacy in man are inhibition of maximal electroshock seizures (MES) and inhibition of pentylenetetrazol (PTZ) convulsions in either rats or mice. SKF 89976A, SKF 100330A and several related compds. were potent inhibitors of PTZ convulsions in rats. SKF 100330A also inhibited MES convulsions in rats. In contrast, neither compd. inhibited MES or electroshock seizure threshold in mice, and whereas both compds. inhibited the tonic phase of PTZ convulsions in approx. 50% of the mice tested, this inhibition was not dose-related. Thus, the rat appears to be a more suitable species for further testing of these compds. The family of compds. represented by SKF 89976A and SKF 100330A may thus have clin. relevant anticonvulsant activity.


IT 89203-55-4

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)

(anticonvulsant activity of and GABA uptake inhibition by)

RN 89203-55-4 CAPLUS

CN 3-Pyrrolidineacetic acid, 1-(4,4-diphenyl-3-butenyl)- (9CI) (CA INDEX NAME)



=> d bib abs 1-9

L28 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2000:493419 CAPLUS

DN 133:109984

TI Compositions for treating frequent urination and urinary incontinence

IN Hashimoto, Tadatoshi; Kamo, Izumi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041728	A1	20000720	WO 2000-JP74	20000111
	W:	AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	JP 2000264848	A2	20000926	JP 2000-6127	20000111
	EP 1142584	A1	20011010	EP 2000-900169	20000111
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI	JP 1999-5556	A	19990112		
	WO 2000-JP74	W	20000111		
AB	A GABA uptake inhibitor is useful in prepg. compns. for treating frequent				

urination and urinary incontinence. Capsules were formulated contg.  
 NO-711-HCl 25, lactose 55, talc 16 and magnesium stearate 4 mg.  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS  
 AN 1997:772607 CAPLUS  
 DN 128:43856  
 TI Use of GABA uptake inhibitors as antitussive agents  
 IN Bondinell, William E.; Underwood, David C.; Kotzer, Charles J.  
 PA Smithkline Beecham Corporation, USA; Bondinell, William E.; Underwood, David C.; Kotzer, Charles J.  
 SO PCT Int. Appl., 12 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9743902	A1	19971127	WO 1997-US8948	19970523
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP	912091	A1	19990506	EP 1997-928667	19970523
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP	2000511538	T2	20000905	JP 1997-542846	19970523
US	6121290	A	20000919	US 1998-194325	19981124
PRAI	US 1996-18258P	P	19960524		
	WO 1997-US8948	W	19970523		
AB	A method is provided for treating cough in a mammal, including a human, which comprises administering an effective amt. of an inhibitor of GABA uptake.				

L28 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS  
 AN 1991:484814 CAPLUS  
 DN 115:84814  
 TI GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative  
 AU N'Goka, Victor; Schlewer, Gilbert; Linget, Jean Michel; Chambon, Jean Pierre; Wermuth, Camille Georges  
 CS Cent. Neurochim., CNRS, Strasbourg, 67084, Fr.  
 SO J. Med. Chem. (1991), 34(8), 2547-57  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 GI




AB A model for the pharmacophore of GABA-uptake inhibitors was established using published structure-activity data and mol. modeling. The model accounted for the activities of different classes of GABA-uptake inhibitors. Analogs of guvacine and nipecotic acid substituted at position 6 were synthesized in order to confirm the model. 6-(3,3-Diphenylpropyl)guvacine (I), which fit well with the pharmacophore,

had an in vitro IC50 of 0.1  $\mu$ M. This value is as good as those of the best GABA-uptake inhibitors known today.

- L28 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS  
AN 1990:509794 CAPLUS  
DN 113:109794  
TI  $\gamma$ -Aminobutyric acid inhibition of histamine-induced inositol phosphate formation in guinea pig cerebellum: comparison with guinea pig and rat cerebral cortex  
AU Crawford, Melissa L. A.; Carswell, Heather; Young, J. M.  
CS Dep. Pharmacol., Univ. Cambridge, Cambridge, CB2 1QJ, UK  
SO Br. J. Pharmacol. (1990), 100(4), 867-73  
CODEN: BJPCBM; ISSN: 0007-1188  
DT Journal  
LA English  
AB  $\gamma$ -Aminobutyric acid (GABA), 2 mM, inhibited basal accumulation of [3H]inositol monophosphate ([3H]-IP1) in lithium-treated slices of guinea pig cerebellum preincubated with [3H]inositol. In contrast, 2 mM GABA stimulated the accumulation of [3H]-IP1 in rat cerebral cortical slices over a 60 min incubation period, but had no significant effect in slices of guinea pig cerebral cortex. The estd. IC50 for the inhibitory action of GABA in guinea pig cerebellar slices was 0.52. GABA inhibited histamine-induced [3H]-IP1 accumulation in guinea pig cerebellar slices in a noncompetitive manner. The best-fit value for the max. level of inhibition was 74%. The estd. IC50 for GABA was 0.77 mM and was not significantly different from the IC50 for inhibition of the basal accumulation of [3H]-IP1. The response to histamine in guinea pig and rat cerebral cortical slices was also inhibited by 2 mM GABA. In guinea pig cerebellar slices 2 mM GABA potentiated histamine-induced [3H]inositol biphosphate ([3H]-IP2) accumulation, whereas in both guinea pig and rat cerebral cortex the effect was inhibition. Isoguvacine and muscimol, GABAA-selective agonists, and (-)-baclofen, GABAB-selective agonist, had no significant effect on basal or histamine-stimulated accumulation of [3H]-IPs in guinea pig cerebellar slices. (-)-Baclofen had only a weak inhibitory effect on [3H]-IP1 accumulation in guinea pig cerebral cortex (16% inhibition with 10  $\mu$ M (-)-baclofen), whereas in rat cerebral cortex (-)-baclofen mimicked the inhibitory effect of GABA. Nipecotic acid (1 mM) had qual. similar effects to those of 2 mM GABA in guinea pig cerebellar slices. The competitive GABA uptake inhibitors SKF 89976A, SKF 100330A, and SKF 100561A were potent histamine H1-receptor antagonists, as indicated by the inhibition of [3H]mepyramine binding to homogenates of guinea pig cerebellum and cerebral cortex. GABA (2 mM) caused a small inhibition (12%) of [3H]inositol incorporation into total inositol phospholipids in guinea pig cerebellar slices, as in rat cerebral cortical slices, whereas 0.2 mM histamine caused a small stimulation (15%). In the presence of both GABA and histamine, [3H]inositol incorporation was unchanged from basal (101%). GABA also inhibited [3H]-IP1 formation induced by endothelin-1 in guinea pig cerebellar slices and increased, but not significantly, the amt. of [3H]-IP2 accumulated. This, taken with the inhibitory effect on basal and histamine-stimulated accumulation, suggests that the action of GABA in guinea pig cerebellar slices may be non-selective and may not be exerted through a specific GABA receptor.
- L28 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS  
AN 1990:152254 CAPLUS  
DN 112:152254  
TI (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain  $\gamma$ -aminobutyric acid uptake carrier  
AU Braestrup, Claus; Nielsen, Erik B.; Sonnewald, Ursula; Knutsen, Lars J. S.; Andersen, Knud Erik; Jansen, Jens Aas; Frederiksen, Kristen; Andersen, Peter H.; Mortensen, Alicja; Suzdak, Peter D.  
CS Novo Ind. A/S, Bagsvaerd, 2880, Den.  
SO J. Neurochem. (1990), 54(2), 639-47

DT Journal  
LA English  
GI



AB NO 328 (I) is a potent inhibitor of [3H]GABA uptake in a rat forebrain synaptosomal prepn. ( $IC_{50} = 67 \text{ nM}$ ) and in primary cultures of neurons and astrocytes. Inhibition of [3H]GABA uptake by NO 328 is apparently of a mixed type when NO 328 is preincubated before [3H]GABA uptake; the inhibition is apparently competitive without preincubation. NO 328 itself is not a substrate for the GABA uptake carrier, but NO 328 is a selective inhibitor of [3H]GABA uptake. Binding to benzodiazepine receptors, histamine H1 receptors, and 5-hydroxytryptamine $1A$  receptors was inhibited by NO 328 at 5-30  $\mu\text{M}$ , whereas several other receptors and uptake sites were unaffected. [3H]NO 328 showed saturable and reversible binding to rat brain membranes in the presence of NaCl. The specific binding of [3H]NO 328 was inhibited by known inhibitors of [3H]GABA uptake; GABA and the cyclic amino acid GABA uptake inhibitors were, however, less potent than expected. This indicates that the binding site is not identical to, but rather overlapping with, the GABA recognition site of the uptake carrier. The affinity const. for binding of [3H]NO 328 is 18 nM, and the  $B_{\text{max}}$  is 669 pmol/g of original rat forebrain tissue. The regional distribution of NaCl-dependent [3H]NO 328 binding followed that of synaptosomal [3H]GABA uptake. Thus, NO 328 is a potent and selective inhibitor of neuronal and glial GABA uptake and [3H]NO 328 is a useful radioligand for labeling the GABA uptake carrier in brain membranes. In the mouse brain in vivo, [3H]NO 328 likewise showed saturable and reversible binding that could be displaced by analogs of NO 328. Further studies are needed to demonstrate whether the uptake carrier is indeed labeled by [3H]NO 328 in vivo.

L28 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 1987:433803 CAPLUS

DN 107:33803

TI A carrier for GABA uptake exists on noradrenaline nerve endings in selective rat brain areas but not on serotonin terminals

AU Bonanno, G.; Raiteri, M.

CS Ist. Farmacol. Farmacogn., Univ. Genova, Genoa, I-16148, Italy

SO J. Neural Transm. (1987), 69(1-2), 59-70

CODEN: JNTMAH; ISSN: 0300-9564

DT Journal

LA English

AB GABA (3-300  $\mu\text{M}$ ) increased, in a concn.-dependent manner, the basal release of tritium from rat cerebral cortex and hippocampus synaptosomes prelabeled with [3H]noradrenaline ([3H]NA); however, GABA was ineffective on hypothalamic nerve endings. The effect displayed by low concns. (<10  $\mu\text{M}$ ) of GABA was largely bicuculline-sensitive. Muscimol mimicked GABA, whereas baclofen was inactive. The releasing effects produced by concns. of GABA >10  $\mu\text{M}$  were largely prevented by SKF 89976A, SKF 100330A, and SKF100561, 3 novel GABA uptake inhibitors. When present together, GABA

uptake blocker and bicuculline counteracted entirely the GABA effects. The release of [3H]5-hydroxytryptamine in synaptosomes from various central nervous system (CNS) regions was not affected by GABA. Apparently, GABA can enhance [3H]NA release not only through GABA-A receptors but also by penetrating into NA terminals through a GABA uptake system. This implies coexistence of carriers for NA and GABA uptake on the same nerve terminal. The carrier coexistence occurs in selective central nervous system areas. The phenomenon appears to be transmitter-selective.

L28 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 1987:208292 CAPLUS

DN 106:208292

TI Regional selectivity of a .gamma.-aminobutyric acid-induced [3H]acetylcholine release sensitive to inhibitors of .gamma.-aminobutyric acid uptake

AU Bonanno, Giambattista; Raiteri, Maurizio

CS Ist. Farmacol. Farmacogn., Univ. Genova, Genoa, 16148, Italy

SO J. Neurochem. (1987), 48(5), 1454-8

CODEN: JONRA9; ISSN: 0022-3042

DT Journal

LA English

AB The effects of GABA [56-12-2] on the release of 3H-labeled acetylcholine (ACh) [51-84-3] were studied in synaptosomes prepd. from rat hippocampus, cerebral cortex, hypothalamus, and striatum and prelabeled with [3H]choline. When synaptosomes were exposed in superfusion to exogenous GABA (0.01-0.3 mM) the basal release of newly synthesized [3H]ACh was increased in a concn.-dependent way in hippocampus, cortex, and hypothalamus nerve endings. In contrast, the release of [3H]ACh was not affected by GABA in striatal synaptosomes. The effect of GABA was not antagonized by bicuculline or picrotoxin. Muscimol caused only a slight insignificant increase of [3H]ACh release when tested at 0.3 mM whereas, at this concn., (-)-baclofen was totally inactive. The GABA-induced release of [3H]ACh was counteracted by SKF 89976A [85375-85-5], SKF 100561 [89203-55-4], and SKF 100330A [85375-88-8], 3 selective GABA uptake inhibitors. In selective areas of the rat brain, GABA causes the release of [3H]ACh following penetration into cholinergic nerve terminals through a GABA transport system.

L28 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 1985:442656 CAPLUS

DN 103:42656

TI N-Substituted pyrrolidineacetic acids and their esters

IN Bondinell, William E.; Lafferty, John J.; Zirkle, Charles L.

PA Smithkline Beckman Corp., USA

SO U.S., 7 pp.




CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4514414	A	19850430	US 1982-436232	19821025
OS	CASREACT 103:42656				
GI					



AB    Pharmaceutical compns. useful as inhibitors of GABA [56-12-2] uptake comprise the title compds. I [R = cyclohexyl, thienyl, or (un)substituted Ph; R1 and R2 = H, Cl, F, Me, or MeO; R3 = H or Me; R4 = H or C1-3 alkyl; n = 2 or 3], II (R1, R2, R3, and R4 as above), and III (R1 and R4 as above) and their optical isomers. I were prepd. by the reaction of an alkenyl halide with an ester of an N-substituted pyrrolidineacetic acid (IV), II were prepd. by the reaction of IV with a diphenylalkyl group, and III were prepd. by the reaction of IV with an ester of an appropriately substituted phenylalkyne. Thus, a capsule formulation contained 1-(4,4-diphenyl-3-butenyl)-3-pyrrolidineacetic acid (I; R = Ph, R1-R4 = H) [89203-55-4] 50, Mg stearate 2, and lactose 200 mg/capsule.

L28    ANSWER 9 OF 10    CAPLUS    COPYRIGHT 2002 ACS

AN    1985:160041    CAPLUS

DN    102:160041

TI    Orally active and potent inhibitors of .gamma.-aminobutyric acid uptake

AU    Ali, Fadia E.; Bondinell, William E.; Dandridge, Penelope A.; Frazee, James S.; Garvey, Eleanor; Girard, Gerald R.; Kaiser, Carl; Ku, Thomas W.; Lafferty, John J.; et al.

CS    Dep. Med. Chem., Smith Kline French Lab., Philadelphia, PA, 19101, USA


SO    J. Med. Chem. (1985), 28(5), 653-60

CODEN: JMCMAR; ISSN: 0022-2623

DT    Journal

LA    English

GI



AB    GABA [56-12-2]-uptake inhibitors that are more potent, more lipophilic, and in limited testing, at least as selective as the parent amino acids were obtained by alkylation of the appropriate butyric-, cyclohexane- and piperidinecarboxylic and pyrrolidineacetic acids. The ability of these

alkylated amino acids to inhibit Na-dependent, high-affinity GABA uptake was measured after preincubation for 15 min with rat brain synaptosomes. N-(4,4-Diphenyl-3-butenyl)-3-piperidinecarboxylic acid (I) [85375-85-5] is a specific GABA-uptake inhibitor more potent, more lipophilic and, as selective as the nonalkylated parent; I and its analogs also exhibited anticonvulsant activity in rodents. Structure-activity relations are discussed.

AN 1991:42580 CAPLUS  
 DN 114:42580  
 TI Preparation of N-(4-heterocyclyl-3-buten-1-yl)guvacines, -nipecotic acids, and -.beta.-homoprolines as central nervous system agents  
 IN Sonnewald, Ursula  
 PA Novo Industri A/S, Den.  
 SO U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 755, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4931450	A	19900605	US 1988-259235	19881017
PRAI	DK 1986-51		19860107		
	DK 1986-956		19860303		
	US 1987-755		19870106		

OS MARPAT 114:42580

AB R1R2C:CHCH2CH2R3 [I; R1 = (un)substituted Ph; R2 = furanyl, thienyl, pyridyl, or pyrrolyl ortho-substituted with C1-7 alkyl or halo; R3 = 3-carboxypiperidin-1-yl, 3-carboxy-1,2,5,6-tetrahydropyridin-1-yl, or 3-(carboxymethyl)pyrrolidin-1-yl] which exhibit .gamma.-aminobutyric acid-uptake inhibitory activity, i.e. selective enhancement of **GABA** activity on the central nervous system, and may be useful for treatment of, e.g. pain, anxiety, and epilepsy, and as sedatives and hypnotics, are prepd. Thus, 1-chloro- and iodo-4-(N-methylpyrrol-2-yl)-4-phenylbut-3-ene were stirred with Et (R)-nipecotate in Me2CO contg. K2CO3 for 12 days at room temp. to give, after sapon. and acidification with aq. HCl, I.HCl [R1 = Ph, R2 = N-methylpyrrol-2-yl, R3 = (R)-3-carboxypiperidin-1-yl] (II). II free base showed an antiepileptic activity with the ratio of ED50 in a rotarod test/ED50 in a sinus tone-induced convulsion test of 28. Tablets and capsules contg. II free base were prepd.


IT 130397-51-2P 130397-54-5P 130397-57-8P  
 130397-60-3P 130397-63-6P 130397-67-0P  
 130397-69-2P 130397-72-7P 130397-75-0P  
 130397-78-3P 130397-81-8P 130397-84-1P  
 130397-87-4P 130397-90-9P 130397-93-2P  
 130397-96-5P 130397-99-8P 130398-02-6P  
 130398-05-9P 130398-07-1P 130398-10-6P  
 130398-13-9P 130398-16-2P 130398-19-5P  
 130398-22-0P 130398-24-2P 130398-26-4P  
 130398-29-7P 130398-32-2P 130398-35-5P  
 130398-38-8P 130398-41-3P 130398-44-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as central nervous system agent)


RN 130397-51-2 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(1-methyl-1H-pyrrol-2-yl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)







RN 130397-54-5 CAPLUS  
 CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(1-methyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-57-8 CAPLUS  
 CN 2-Piperidinecarboxylic acid, 1-[4-(3-methyl-2-thienyl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-60-3 CAPLUS  
 CN 2-Piperidinecarboxylic acid, 1-[4-(1-ethyl-1H-pyrrol-2-yl)-4-(2-methylphenyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-63-6 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(1-propyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-67-0 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-69-2 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[4-(2-ethylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-72-7 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2-ethylphenyl)-4-(3-ethyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)

RN 535-75-1 REGISTRY  
 CN 2-Piperidinecarboxylic acid (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Pipecolic acid (8CI)  
 OTHER NAMES:  
 CN (.+-.)-2-Piperidinecarboxylic acid  
 CN (.+-.)-Pipecolic acid  
 CN (.+-.)-Pipecolinic acid  
 CN (RS)-2-Piperidinecarboxylic acid  
 CN .alpha.-Pipecolinic acid  
 CN 2-Carboxypiperidine  
 CN Dihydrobaikiane  
 CN DL-2-Piperidinecarboxylic acid  
 CN DL-Pipecolic acid  
 CN DL-Pipecolinic acid  
 CN Hexahydro-2-picolinic acid  
 CN **Homoproline**  
 CN Pipecolinic acid  
 CN Piperolinic acid  
 FS 3D CONCORD  
 DR 4043-87-2  
 MF C6 H11 N O2  
 CI COM  
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS,  
 CHEMINFORMRX, CHEMLIST, CSCHM, DDFU, DRUGU, EMBASE, GMELIN\*, HODOC\*,  
 IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK\*, NAPRALERT, PROMT, RTECS\*,  
 SYNTHLINE, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

673 REFERENCES IN FILE CA (1962 TO DATE)  
 50 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 674 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

AN 1991:42580 CAPLUS  
 DN 114:42580  
 TI Preparation of N-(4-heterocyclyl-3-buten-1-yl)guvacines, -nipecotic acids, and -.beta.-homoprolines as central nervous system agents  
 IN Sonnewald, Ursula  
 PA Novo Industri A/S, Den.  
 SO U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 755, abandoned.  
 CODEN: USXXAM

DT Patent  
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4931450	A	19900605	US 1988-259235	19881017
PRAI	DK 1986-51		19860107		
	DK 1986-956		19860303		
	US 1987-755		19870106		

OS MARPAT 114:42580


AB R1R2C:CHCH2CH2R3 [I; R1 = (un)substituted Ph; R2 = furanyl, thienyl, pyridyl, or pyrrolyl ortho-substituted with C1-7 alkyl or halo; R3 = 3-carboxypiperidin-1-yl, 3-carboxy-1,2,5,6-tetrahydropyridin-1-yl, or 3-(carboxymethyl)pyrrolidin-1-yl] which exhibit .gamma.-aminobutyric acid-uptake inhibitory activity, i.e. selective enhancement of GABA activity on the central nervous system, and may be useful for treatment of, e.g. pain, anxiety, and epilepsy, and as sedatives and hypnotics, are prepd. Thus, 1-chloro- and iodo-4-(N-methylpyrrol-2-yl)-4-phenylbut-3-ene were stirred with Et (R)-nipecotate in Me2CO contg. K2CO3 for 12 days at room temp. to give, after sapon. and acidification with aq. HCl, I.HCl [R1 = Ph, R2 = N-methylpyrrol-2-yl, R3 = (R)-3-carboxypiperidin-1-yl] (II). II free base showed an antiepileptic activity with the ratio of ED50 in a rotarod test/ED50 in a sinus tone-induced convulsion test of 28. Tablets and capsules contg. II free base were prepd.

IT 130397-51-2P 130397-54-5P 130397-57-8P  
 130397-60-3P 130397-63-6P 130397-67-0P  
 130397-69-2P 130397-72-7P 130397-75-0P  
 130397-78-3P 130397-81-8P 130397-84-1P  
 130397-87-4P 130397-90-9P 130397-93-2P  
 130397-96-5P 130397-99-8P 130398-02-6P  
 130398-05-9P 130398-07-1P 130398-10-6P  
 130398-13-9P 130398-16-2P 130398-19-5P  
 130398-22-0P 130398-24-2P 130398-26-4P  
 130398-29-7P 130398-32-2P 130398-35-5P  
 130398-38-8P 130398-41-3P 130398-44-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as central nervous system agent)


RN 130397-51-2 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(1-methyl-1H-pyrrol-2-yl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-54-5 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(1-methyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-57-8 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3-methyl-2-thienyl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-60-3 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(1-ethyl-1H-pyrrol-2-yl)-4-(2-methylphenyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-63-6 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(1-propyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-67-0 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-69-2 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2-ethylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-72-7 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2-ethylphenyl)-4-(3-ethyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-75-0 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(1-ethyl-1H-pyrrol-2-yl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-78-3 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(4-fluorophenyl)-4-(1-methyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-81-8 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3-methyl-2-furanyl)-4-(2-methylphenyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-84-1 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2,4-dimethylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-87-4 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(4-chloro-2-methylphenyl)-4-(1-methyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130397-90-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(4-chloro-2-methylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-93-2 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[4-(2-fluorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-96-5 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[4-(2,3-dimethoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)






RN 130397-99-8 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(4-chlorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-02-6 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3-chlorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-05-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2,5-dimethoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-07-1 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3,5-dichlorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-10-6 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3,4-dichlorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-13-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2,4-dichlorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-16-2 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2-methoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-19-5 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3-methoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-22-0 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3,5-dimethoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-24-2 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2,6-dimethoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-26-4 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(4-fluoro-2-methylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-29-7 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3-chloro-2-methylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-32-2 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3,4-dimethoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-35-5 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3-chloro-2-thienyl)-4-(2-methylphenyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-38-8 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3-bromo-2-thienyl)-4-(2-methylphenyl)-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-41-3 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3-chloro-2-thienyl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)




RN 130398-44-6 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(3-bromo-2-thienyl)-4-phenyl-3-butenyl]-  
(9CI) (CA INDEX NAME)



RN 498-95-3 REGISTRY  
 CN 3-Piperidinecarboxylic acid (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN **Nipecotic acid** (6CI, 7CI, 8CI)  
 OTHER NAMES:  
 CN (.+-.)-.beta.-Homoproline  
 CN (.+-.)-Nipecotic acid  
 CN 3-Carboxypiperidine  
 CN DL-Nipecotic acid  
 CN Hexahydronicotinic acid  
 FS 3D CONCORD  
 DR 60252-41-7  
 MF C6 H11 N O2  
 CI COM  
 LC STN Files: AGRICOLA, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,  
 CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST,  
 CSCHM, DDFU, DRUGU, EMBASE, HODOC\*, IPA, MEDLINE, MRCK\*, TOXCENTER,  
 USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

316 REFERENCES IN FILE CA (1962 TO DATE)  
 18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 316 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s guvacine/cn  
 L2 1 GUVACINE/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
 RN 498-96-4 REGISTRY  
 CN 3-Pyridinecarboxylic acid, 1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Nicotinic acid, 1,2,5,6-tetrahydro- (8CI)  
 OTHER NAMES:  
 CN 1,2,5,6-Tetrahydronicotinic acid  
 CN **Guvacine**  
 FS 3D CONCORD  
 MF C6 H9 N O2  
 CI COM  
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CSCHM, DDFU,  
 DRUGU, EMBASE, HODOC\*, MEDLINE, MRCK\*, NAPRALERT, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)






**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

76 REFERENCES IN FILE CA (1962 TO DATE)

7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

76 REFERENCES IN FILE CAPLUS (1962 TO DATE)



AB Pharmaceutical compns. useful as inhibitors of GABA [56-12-2] uptake comprise the title compds. I [R = cyclohexyl, thienyl, or (un)substituted Ph; R1 and R2 = H, Cl, F, Me, or MeO; R3 = H or Me; R4 = H or C1-3 alkyl; n = 2 or 3], II, (R1, R2, R3, and R4 as above), and III (R1 and R4 as above) and their optical isomers. I were prepd. by the reaction of an alkenyl halide with an ester of an N-substituted pyrrolidineacetic acid (IV), II were prepd. by the reaction of IV with a diphenylalkyl group, and III were prepd. by the reaction of IV with an ester of an appropriately substituted phenylalkyne. Thus, a capsule formulation contained 1-(4,4-diphenyl-3-butenyl)-3-pyrrolidineacetic acid (I; R = Ph, R1-R4 = H) [89203-55-4] 50, Mg stearate 2, and lactose 200 mg/capsule.

L28 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 1985:160041 CAPLUS

DN 102:160041

TI Orally active and potent inhibitors of .gamma.-aminobutyric acid uptake

AU Ali, Fadia E.; Bondinell, William E.; Dandridge, Penelope A.; Frazee, James S.; Garvey, Eleanor; Girard, Gerald R.; Kaiser, Carl; Ku, Thomas W.; Lafferty, John J.; et al.

CS Dep. Med. Chem., Smith Kline French Lab., Philadelphia, PA, 19101, USA


SO J. Med. Chem. (1985), 28(5), 653-60

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English


GI



AB GABA [56-12-2]-uptake inhibitors that are more potent, more lipophilic, and in limited testing, at least as selective as the parent amino acids were obtained by alkylation of the appropriate butyric-, cyclohexane- and piperidinecarboxylic and pyrrolidineacetic acids. The ability of these



alkylated amino acids to inhibit Na-dependent, high-affinity GABA uptake was measured after preincubation for 15 min with rat brain synaptosomes. N-(4,4-Diphenyl-3-butenyl)-3-piperidinecarboxylic acid (I) [85375-85-5] is a specific GABA-uptake inhibitor more potent, more lipophilic and, as selective as the nonalkylated parent; I and its analogs also exhibited anticonvulsant activity in rodents. Structure-activity relations are discussed.



ENTER (DIS), GRA, NOD, BON OR ?:end

L1 STRUCTURE CREATED

=> s l1

SAMPLE SEARCH INITIATED 13:00:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 27460 TO ITERATE

3.6% PROCESSED 1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 539324 TO 559076

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> screen 1840

L3 SCREEN CREATED

=> s l1 and l3

SAMPLE SEARCH INITIATED 13:01:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 18773 TO ITERATE

5.3% PROCESSED 1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 367277 TO 383643

PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L1 AND L3

=> s l1 and l3 ful


FULL SEARCH INITIATED 13:01:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 376379 TO ITERATE

100.0% PROCESSED 376379 ITERATIONS  
SEARCH TIME: 00.00.36

0 ANSWERS

L5 0 SEA SSS FUL L1 AND L3



VPA 15-2/1/5 U  
 ENTER (DIS), GRA, NOD, BON OR ?:end  
 L10 STRUCTURE CREATED

=> s l10  
 SAMPLE SEARCH INITIATED 13:04:53 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 27460 TO ITERATE

3.6% PROCESSED 1000 ITERATIONS  
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 539324 TO 559076  
 PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L10

=> s l10 and l3  
 SAMPLE SEARCH INITIATED 13:04:59 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 18773 TO ITERATE

5.3% PROCESSED 1000 ITERATIONS  
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 367277 TO 383643  
 PROJECTED ANSWERS: 0 TO 0

L12 0 SEA SSS SAM L10 AND L3

=> s l10 and l3 ful  
 FULL SEARCH INITIATED 13:05:04 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 376379 TO ITERATE

69.9% PROCESSED 263210 ITERATIONS


0 ANSWERS

100.0% PROCESSED 376379 ITERATIONS  
 SEARCH TIME: 00.00.37

0 ANSWERS

L13 0 SEA SSS FUL L10 AND L3

L17 HAS NO ANSWERS  
L17 STR



VAR G1=O/S  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RSPEC 1  
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE


=> s l17 ful  
FULL SEARCH INITIATED 13:08:50 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 314381 TO ITERATE

92.1% PROCESSED 289554 ITERATIONS 0 ANSWERS

100.0% PROCESSED 314381 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.23

L20 0 SEA SSS FUL L17

=> d l17  
 L17 HAS NO ANSWERS  
 L17 STR



REP G1=(0-5) CH2  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RSPEC 1  
 NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

=> s l17 ful  
 FULL SEARCH INITIATED 12:06:05 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 225006 TO ITERATE

93.7% PROCESSED 210817 ITERATIONS	24 ANSWERS
100.0% PROCESSED 225006 ITERATIONS	24 ANSWERS
SEARCH TIME: 00.00.47	

L19 24 SEA SSS FUL L17

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	144.84	145.05

FILE 'CAPLUS' ENTERED AT 12:07:01 ON 25 JUL 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jul 2002 VOL 137 ISS 4

FILE LAST UPDATED: 24 Jul 2002 (20020724/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l19

L20 5 L19

=> d bib abs 1-5

L20 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS  
AN 2001:132748 CAPLUS  
DN 134:178816  
TI Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders  
IN Ognyanov, Vassil Iliya; Borden, Laurence A.; Bell, Stanley Charles; Zhang, Jing  
PA Allelix Neuroscience Inc., USA  
SO U.S., 52 pp., Cont.-in-part of U. S. Ser. No.656,063, abandoned.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 6191165	B1	20010220	US 1997-866007	19970530
	US 2001012857	A1	20010809	US 2001-757011	20010109
PRAI	US 1996-41503P	P	19960531		
	US 1996-41504P	P	19960531		
	US 1996-655912	B2	19960531		
	US 1996-656063	B2	19960531		
	US 1997-44387P	P	19970227		
	US 1997-70900P	P	19970227		
	US 1997-808754	B2	19970227		
	US 1997-808755	A2	19970227		
	US 1997-807682	A2	19970228		
	US 1997-866007	A3	19970530		

OS MARPAT 134:178816

AB Amino acid derivs. R2RxRyXR1NR3(R3\*)nCR4R4\*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminoxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3\* = alkyl, O; n = 0, 1; R4, R4\* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS


AN 2000:157915 CAPLUS

DN 132:194656

TI Preparation of proline derivatives and related compounds as GABA uptake inhibitors

IN Wanner, Klaus; Fuelep, Guenther; Hoefner, Georg  
 PA Germany  
 SO Ger. Offen., 36 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19840611	A1	20000309	DE 1998-19840611	19980905
	WO 2000014064	A2	20000316	WO 1999-EP6486	19990903
	WO 2000014064	A3	20000720		
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9959726	A1	20000327	AU 1999-59726	19990903
	EP 1109783	A2	20010627	EP 1999-968664	19990903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	DE 1998-19840611	A	19980905		
	WO 1999-EP6486	W	19990903		
OS	MARPAT 132:194656				
GI					





AB Title compds. [I; R1-R7 = H, OH, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) aryl, heteroaryl, etc.; R1R2 and/or R3R4 and/or R5R6 = (substituted) alkylidene, O; pairs of adjoining R1-R7 = double bond; X = CO2M, group physiol. convertible to CO2M; M = H, pharmaceutically acceptable cation; Z = Y3CO, Y2C:CR15, Y2C:NO; R15 = H, alkyl, halo; Y = (substituted) aryl, heteroaryl; A1 = (CR8R9)n, (substituted) alkylene, or a combination thereof; n .gtoreq.2; R8, R9 = H, alkyl, halo, OH, etc.; A2 = (CR10R11)m; R10, R11 = H, alkyl, halo; m .gtoreq.2], were prepd. as GABA uptake inhibitors (no data). Thus, L-proline Me ester hydrochloride (prepn. given), KI, K2CO3, and 4,4-diphenylbut-3-en-1-yl bromide were stirred 46 h in acetone to give 52.4% Me (S)-N-(4,4-diphenylbut-3-en-1-yl)pyrrolidine-2-carboxylate.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS  
 AN 1998:668212 CAPLUS  
 DN 130:24646  
 TI Asymmetric allylations of chiral enamines via 1,3-diphenyl-.pi.-allylnickel complexes  
 AU Hiroi, Kunio; Endo, Taichi; Kato, Fumiko  
 CS Tohoku Coll. Pharm., Sendai, 981-8558, Japan  
 SO Annual Report of the Tohoku College of Pharmacy (1997), 44, 127-134  
 CODEN: TYKNAQ; ISSN: 0495-7342  
 PB Tohoku Yakka Daigaku  
 DT Journal  
 LA Japanese  
 OS CASREACT 130:24646

GI



AB Ni-catalyzed asym. allylation of 2-phenylpropanal or 2,2-diphenylacetaldehyde with 1,3-diphenylpropenyl acetate to 2-methyl-2,3,5-triphenyl-4-propenal derivs. (I and II) or 2-phenyl-2,3,5-triphenyl-4-propanal (III), resp., was carried out via chiral enamines (styrylproline derivs.) [(S)-IV; R = CH<sub>2</sub>OH, CO<sub>2</sub>CMe<sub>3</sub>, 1-pyrrolidinylcarbonyl, CH<sub>2</sub>PPh<sub>2</sub>; R<sub>1</sub> = Me, Ph] derived from the aldehydes and (S)-proline derivs. (V; R = same as above). A plausible mechanism of the asym. induction is proposed on the basis of stereochem. of the chiral enamines employed and the corresponding Ni complexes formed. Thus, a soln. of 0.447 mmol 1,3-diphenylpropenyl acetate in THF was added to 0.037 mmol bis(1,5-cyclooctadiene)nickel (Ni(COD)<sub>2</sub>) and 0.074 mmol 1,4-bis(diphenylphosphino)butane (dppb) and stirred for 30 min at room temp., followed by adding a soln. of 0.373 mmol (S)-IV (R = CH<sub>2</sub>OH) in THF, and the resulting mixt. was stirred for 72 h at room temp., treated with 10% aq. HCl and benzene, and refluxed for 1 h to give a mixt. of I (42% ee) and II (34% ee) in 75% yield.

L20 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS

AN 1997:803807 CAPLUS

DN 128:48490

TI Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders

IN Ognyanov, Vassil Iliya; Borden, Laurence; Bell, Stanley Charles; Zhang, Jing

PA Trophix Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9745115	A1	19971204	WO 1997-US9450	19970529
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2254833	AA	19971204	CA 1997-2254833	19970529
AU 9731530	A1	19980105	AU 1997-31530	19970529



AU 730789 B2 20010315  
 EP 1014966 A1 20000705 EP 1997-926871 19970529  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 BR 9709501 A 20001107 BR 1997-9501 19970529  
 CN 1327383 A 20011219 CN 1997-196821 19970529  
 JP 2002515037 T2 20020521 JP 1997-543034 19970529  
 NO 9805711 A 19981207 NO 1998-5711 19981207  
 PRAI US 1996-655912 A 19960531  
 US 1996-656063 A 19960531  
 US 1997-808754 A 19970227  
 US 1997-808755 A 19970227  
 US 1997-807682 A 19970227  
 WO 1997-US9450 W 19970529  
 OS MARPAT 128:48490  
 AB Amino acid derivs. R2RxRyXR1NR3(R3\*)nCR4R4\*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminoxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3\* = alkyl, O; n = 0, 1; R4, R4\* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.

L20 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS  
 AN 1986:50792 CAPLUS  
 DN 104:50792  
 TI Anti-histamine compounds  
 IN Coker, Geoffrey George; Findlay, John William Addison  
 PA Wellcome Foundation Ltd., UK  
 SO Brit. UK Pat. Appl., 12 pp.  
 CODEN: BAXXDU  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2145081	A1	19850320	GB 1984-19264	19840727
	GB 2145081	B2	19860716		
	US 4610995	A	19860909	US 1984-635309	19840727
PRAI	GB 1983-20704		19830801		
GI					



AB Amines I (R1 = H, alkyl; R2 = substituted alkyl; R1R2N = substituted N-contg. heterocycle; R3 = H, halo, OH, cyano, acyloxy, alkoxy, alkyl; R4

= R5 = H, R4R5 = bond; Z = N, CH) and their salts, useful as antihistaminics (data given), were prepd. Thus, treating L-proline Et ester with (2-phenoxyethyl)triphenylphosphonium bromide in EtOH gave [2-(2-ethoxycarbonylpyrrolidino)ethyl]triphenylphosphonium bromide, Wittig reaction of which with 2-(4-toluoyl)pyridine gave, after isomerization and sapon. with H2SO4, (E)-1-[3-(2-pyridyl)-3-14-tolylprop-2-enyl]pyrrolidine-2-carboxylic acid. Pharmaceutical formulations of I are presented.

AN 1997:724891 CAPLUS  
 DN 128:18717  
 TI GABAA, NMDA and AMPA receptors: a developmentally regulated 'menage a trois'  
 AU Ben-Ari, Yehezkel; Khazipov, Roustem; Leinekugel, Xavier; Caillard, Olivier; Gaiarsa, Jean-Luc  
 CS Hopital Port-Royal, Institut National Sante Recherche Medicale, Paris, 75014, Fr.  
 SO Trends in Neurosciences (1997), 20(11), 523-529  
 CODEN: TNSCDR; ISSN: 0166-2236  
 PB Elsevier  
 DT Journal; **General Review**  
 LA English  
 AB A review, with 101 refs., of the functional maturation of GABAergic and glutamatergic synaptic transmissions in the CNS. The main ionotropic receptors (GABAA, **NMDA** and AMPA) display a sequential participation in neuronal excitation in the neonatal hippocampus. **GABA**, the principal inhibitory transmitter in the adult CNS, acts as an excitatory transmitter in early postnatal stage. Glutamatergic synaptic transmission is first purely **NMDA**-receptor based and lacks functional AMPA receptors. Therefore, initially glutamatergic synapses are 'silent' at resting membrane potential, **NMDA** channels being blocked by Mg<sup>2+</sup>. However, when **GABA** and glutamatergic synapses are coactivated during the physiol. patterns of activity, GABAA receptors can facilitate the activation of **NMDA** receptors, playing the role conferred to AMPA receptors later on in development. Detg. the mechanisms underlying the development of this 'menage a trois' will shed light not only on the wide range of trophic roles of glutamate and **GABA** in the developing brain, but also on the significance of the transition from neonatal to adult forms of plasticity.


New search for structure  
by color

9/8/03

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-[4-(3-chlorophenyl)-4-phenyl-3-butenyl]-,  
methyl ester, (E)- (9CI)  
MF C23 H26 Cl N O2

Double bond geometry as shown.


US 4,514,419  
Structures



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):59


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Methanone, cyclohexylphenyl- (9CI)  
MF C13 H16 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-[4-(3-chlorophenyl)-4-phenyl-3-butenyl]-,  
hydrochloride, (E)- (9CI)  
MF C22 H24 Cl N O2 . Cl H

Double bond geometry as shown.



● HCl


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Cyclopropane, bromo- (6CI, 7CI, 8CI, 9CI)  
 MF C3 H5 Br  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-(4-fluorophenyl)-4-phenyl-3-butenyl]-,  
 methyl ester, (E)- (9CI)  
 MF C23 H26 F N O2

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, 1,1'-(4-bromo-1-butenylidene)bis- (9CI)  
 MF C16 H15 Br




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-(4-fluorophenyl)-4-phenyl-3-butenyl]-,  
 hydrochloride, (E)- (9CI)  
 MF C22 H24 F N O2 . Cl H

Double bond geometry as shown.




L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetonitrile, 1-(phenylmethyl)- (9CI)  
 MF C13 H16 N2  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4,4-bis(4-fluorophenyl)-3-butenyl]-, methyl  
 ester (9CI)  
 MF C23 H25 F2 N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-4-chloro-, (E)- (9CI)  
 MF C16 H14 Br Cl

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-(5,5-diphenyl-4-pentenyl)-, methyl ester (9CI)  
 MF C24 H29 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-3-chloro-, (E)- (9CI)  
 MF C16 H14 Br Cl

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-(5,5-diphenylpentyl)-, methyl ester (9CI)  
 MF C24 H31 N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-4-fluoro-, (E)- (9CI)  
 MF C16 H14 Br F

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-(4-cyclohexyl-4-phenyl-3-butenyl)-, methyl ester, (E)- (9CI)


MF C23 H33 N O2

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzenemethanol, .alpha.-(4-methoxybutyl)-.alpha.-phenyl- (9CI)  
MF C18 H22 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-(4-cyclohexyl-4-phenyl-3-butenyl)-,  
hydrochloride, (E)- (9CI)  
MF C22 H31 N O2 . Cl H


Double bond geometry as shown.



● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, (4-bromo-1-cyclohexyl-1-butenyl)-, (E)- (9CI)  
 MF C16 H21 Br


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-phenyl-4-(2-thienyl)-3-butenyl]-, methyl  
 ester, (E)- (9CI)  
 MF C21 H25 N O2 S


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Thiophene, 2-(4-bromo-1-phenyl-1-butenyl)-, (E)- (9CI)  
 MF C14 H13 Br S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-[4-phenyl-4-(2-thienyl)-3-butenyl]-, (E)-,  
cyclohexylsulfamate (9CI)  
MF C20 H23 N O2 S . C6 H13 N O3 S

CM 1


Double bond geometry as shown.



CM 2




L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-(4,4-diphenyl-3-butenyl)- (9CI)  
MF C22 H25 N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-(4-phenyl-3-butynyl)-, methyl ester (9CI)  
MF C17 H21 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-(phenylmethyl)-, methyl ester,  
 cyclohexylsulfamate (9CI)  
 MF C14 H19 N O2 . C6 H13 N O3 S


CM 1



CM 2




L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Butanoic acid, 4-amino- (9CI)  
 MF C4 H9 N O2  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-(4,4-diphenylbutyl)-, (2Z)-2-butenedioate  
 (1:1) (9CI)  
 MF C22 H27 N O2 . C4 H4 O4

CM 1




CM 2

Double bond geometry as shown.




L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, 1-bromo-3-chloro- (6CI, 8CI, 9CI)  
 MF C6 H4 Br Cl  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-(4-chlorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (Z)- (9CI)  
 MF C23 H26 Cl N O2

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Methanone, (4-chlorophenyl)phenyl- (9CI)  
 MF C13 H9 Cl O  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-(4-chlorophenyl)-4-phenyl-3-butenyl]-,  
 hydrochloride, (Z)- (9CI)  
 MF C22 H24 Cl N O2 . Cl H


Double bond geometry as shown.



● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Methanone, (4-fluorophenyl)phenyl- (9CI)  
 MF C13 H9 F O  
 CI COM






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-(3-chlorophenyl)-4-phenyl-3-butenyl]-,  
 methyl ester, (Z)- (9CI)  
 MF C23 H26 Cl N O2

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Methanone, (3-chlorophenyl)phenyl- (9CI)  
 MF C13 H9 Cl O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-(3-chlorophenyl)-4-phenyl-3-butenyl]-,  
 hydrochloride, (Z)- (9CI)  
 MF C22 H24 Cl N O2 . Cl H

Double bond geometry as shown.





● HCl


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Butane, 1-bromo-4-methoxy- (9CI)  
 MF C5 H11 Br O

Br- (CH<sub>2</sub>)<sub>4</sub>-O-Me

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-(4-fluorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (Z)- (9CI)  
 MF C23 H26 F N O2


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Butyn-1-ol, 4-phenyl- (7CI, 8CI, 9CI)


MF C10 H10 O  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-[4-(4-fluorophenyl)-4-phenyl-3-butenyl]-,  
hydrochloride, (Z)- (9CI)  
MF C22 H24 F N O2 . Cl H

Double bond geometry as shown.




● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzene, 1,1'-(4-bromo-1-butenylidene)bis[4-fluoro- (9CI)  
MF C16 H13 Br F2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-[4,4-bis(4-fluorophenyl)-3-butenyl]-,  
hydrochloride (9CI)  
MF C22 H23 F2 N O2 . Cl H




L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-4-chloro-, (Z)- (9CI)  
 MF C16 H14 Br Cl

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-(5,5-diphenyl-4-pentenyl)-, hydrochloride  
 (9CI)  
 MF C23 H27 N O2 . Cl H



● HCl


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-3-chloro-, (Z)- (9CI)  
 MF C16 H14 Br Cl

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-(5,5-diphenylpentyl)-, hydrochloride (9CI)  
 MF C23 H29 N O2 . Cl H



● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-4-fluoro-, (Z)- (9CI)  
 MF C16 H14 Br F


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-(4-cyclohexyl-4-phenyl-3-butenyl)-, methyl ester, (Z)- (9CI)  
 MF C23 H33 N O2

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, 1,1'-(5-bromo-1-pentenylidene)bis- (9CI)  
 MF C17 H17 Br



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-(4-cyclohexyl-4-phenyl-3-butenyl)-,  
 hydrochloride, (Z)- (9CI)  
 MF C22 H31 N O2 . Cl H


Double bond geometry as shown.



● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzene, (4-bromo-1-cyclohexyl-1-butenyl)-, (Z)- (9CI)  
 MF C16 H21 Br


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-phenyl-4-(2-thienyl)-3-butenyl]-, methyl  
 ester, (Z)- (9CI)  
 MF C21 H25 N O2 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Thiophene, 2-(4-bromo-1-phenyl-1-butenyl)-, (Z)- (9CI)

MF C14 H13 Br S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-[4-phenyl-4-(2-thienyl)-3-butenyl]-, (Z)-, cyclohexylsulfamate (9CI)  
MF C20 H23 N O2 S . C6 H13 N O3 S

CM 1


Double bond geometry as shown.



CM 2




L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI)  
MF C23 H27 N O2  
CI COM



#


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 3-Pyrrolidineacetic acid, 1-(4-phenyl-3-butenyl)- (9CI)  
MF C16 H19 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, methyl ester, cyclohexylsulfamate (9CI)  
 MF C7 H13 N O2 . C6 H13 N O3 S  
 CM 1



CM 2



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzonitrile (8CI, 9CI)  
 MF C7 H5 N  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-(4-chlorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (E)- (9CI)  
 MF C23 H26 Cl N O2


Double bond geometry as shown.





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Methanone, diphenyl- (9CI)  
 MF C13 H10 O  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 3-Pyrrolidineacetic acid, 1-[4-(4-chlorophenyl)-4-phenyl-3-butenyl]-,  
 hydrochloride, (E)- (9CI)  
 MF C22 H24 Cl N O2 . Cl H

Double bond geometry as shown.

O=C(c1ccsc1)c2ccccc2

**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***